London Daily

Focus on the big picture.
Monday, Aug 25, 2025

Shanghai and Shenzhen stock markets are shaping up as viable rivals to Hong Kong in the race for the biotech IPO crown

Shanghai and Shenzhen stock markets are shaping up as viable rivals to Hong Kong in the race for the biotech IPO crown

Sixteen pre-profit biotech firms have raised a combined US$4.5 billion in Hong Kong since April 2018, compared with two listings on Nasdaq that raised US$264 million in the same period. Last year, Shanghai’s regulators allowed drug developers that have yet to earn a revenue or profit to raise funds on the Star market, followed recently by a similar green light on the ChiNext market in Shenzhen
Shanghai and Shenzhen are shaping up as viable destinations for biotech researchers to raise capital, after they drafted or enacted new rules that match Hong Kong’s overture to pre-revenue pharmaceutical and health care start-ups, bankers said.

Last year, Shanghai’s financial regulators allowed drug developers that have yet to earn a revenue or profit to raise funds via initial public offerings (IPOs) on the Science and Technology Innovation Market (Star), followed recently by a similar green light on the ChiNext stock market in Shenzhen. The changes on the two bourses match Hong Kong’s April 2018 listing rule reform, which propelled the local stock exchange to become the world’s second-largest market for biotech IPOs after New York.

“Hong Kong is still positioned as the number one IPO destination for leading Chinese biotech companies, especially those seeking overseas listings, thanks to its mature and stable legal system and abundant international capital,” said Tang Jing, who helps Chinese biotech companies raise capital and pick IPO venues as vice-president of the health care and life science investment banking team at China Renaissance. “However, we saw a change in the dynamics last year, which is speeding up this year due to rapid policy moves.”

The changes afoot reflect the competition between the three stock exchanges – Hong Kong, Shanghai and Shenzhen – to claim the crown as the go-to destination for Chinese companies. Hong Kong, with US$4.99 trillion in capitalisation as of May 15, is the biggest stand-alone stock market of the three, based on Bloomberg data, surpassing Shanghai’s US$4.94 trillion and Shenzhen’s US$1.07 trillion.

A raft of regulatory differences divide the three markets, not least China’s capital control that constrain IPOs in Shanghai and Shenzhen to raising capital denominated in renminbi. On top of the currency limitation, China’s financial regulators typically require IPO applicants to show several years of profit, while the process of approving stock sales are often subject to capricious policy shifts that may leave companies in the queue for years.

“Yuan funds raised in mainland markets can’t be readily converted into foreign currencies, making it more difficult for companies to finance overseas projects with the proceeds,” giving Hong Kong an advantage, said Samuel Ng, a partner at the international law firm Paul Hastings, who advises listing candidates.

For companies that want to tap global investors, Hong Kong has become the preferred destination, which explains why 16 pre-profit biotech companies have listed since April 2018, raising a combined US$4.5 billion. By comparison, two pre-profit drug developers listed on Nasdaq over the same period, raising US$264 million, according to Refinitiv.

Shanghai’s overture to pre-revenue start-ups have attracted two listing since mid-2019, with US$574 million raised. They add to 13 profitable pharmaceutical companies and research teams in diagnostics, medical devices and development services on the Star market. Together the 15 firms raised US$2.3 billion in capital.

ChiNext’s proposed rules – under market consultation – would open the door for unprofitable firms to list, provided they have at least 300 million yuan in sales in the latest financial year and attain a market value of at least 5 billion yuan when listed.

“The registration-based system to be adopted by ChiNext will provide another exit option for shareholders of biotech companies in China, beyond Hong Kong, New York and Shanghai,” Tang said.

Under Star’s rules, drug developers without profit or revenue are allowed to list, if they have at least one drug candidate with promising market potential – on which phase-two clinical trials have started – and a market value of over 4 billion yuan upon listing.

In Hong Kong, the biotech listing regime let drug and medical device developers with no revenue or profit to go public if they meet requirements including a market value of at least HK$1.5 billion upon listing and at least one drug candidate having regulators’ consent to start phase two trials.

Bucking the global stock market slump, InnoCare Pharma and Akeso saw their over HK$2 billion IPOs “very significantly oversubscribed” by institutional investors, while retail investors committed funds to buy 299 and 639 times the shares available respectively.

Tang attributed the boom to a perception of the health care sector’s defensiveness, its long term growth potential in China, as well as the limited number of quality biotech firms listed in Hong Kong.

Houston Huang Guobin, JP Morgan’s head of global investment banking for China, said the China biotech IPO deals pipeline is “very strong”, especially in Hong Kong. However, he cautioned retail investors to maintain a disciplined approach.

“There will always be people, having made money on their first biotech IPO, would assume they can repeat that in the second one,” he said. “Careful company analysis should be done every time, as not every company is the same.”

To be sure, IPOs are not zero-sum games, as companies with global ambitions may choose to list in multiple markets, said Christian Hogg, CEO of the novel drugs developer Hutchison China Meditech, or Chi-Med, whose shares are traded in London and New York. Chi-Med, headquartered in Hong Kong and a unit of tycoon Li Ka-shing’s CK Hutchison, operates mainly in mainland China.

“I don’t believe it is all about who’s going to win,” Hogg said, adding that at some point a Hong Kong listing may make sense to Chi-Med. “It is about building a multi-pillar equity capital market ecosystem that can feed the necessary capital into the industry to enable new drugs to be brought to China and beyond.”
Newsletter

Related Articles

0:00
0:00
Close
Vietnam Evacuates Hundreds of Thousands as Typhoon Kajiki Strikes; China’s Sanya Shuts Down
UK Government Delays Decision on China’s Proposed London Embassy Amid Concerns Over Redacted Plans
A 150-Year Tradition to Be Abolished? Uproar Over the Popular Central Park Attraction
A new faith called Robotheism claims artificial intelligence isn’t just smart but actually God itself
Deputy Prime Minister Angela Rayner Purchases Third Property Amid Housing Tax Reforms Debate
HSBC Switzerland Ends Relationships with Over 1,000 Clients from Saudi Arabia, Lebanon, Qatar, and Egypt
Sharia Law Made Legally Binding in Austria Despite Warnings Over 'Incompatible' Values
Italian Facebook Group Sharing Intimate Images Without Consent Shut Down Amid Police Investigation
Dutch Foreign Minister Resigns Amid Deadlock Over Israel Sanctions
Trump and Allies Send Messages of Support to Ukraine on Independence Day Amid Ongoing Conflict
China Reels as Telegram Chat Group Shares Hidden-Camera Footage of Women and Children
Sam Nicoresti becomes first transgender comedian to win Edinburgh Comedy Award
Builders uncover historic human remains in Lancashire house renovation
Australia Wants to Tax Your Empty Bedrooms
MotoGP Cameraman Narrowly Avoids Pedro Acosta Crash at Hungarian Grand Prix
FBI Investigates John Bolton Over Classified Documents in High-Profile Raids
Report reveals OpenAI pitched national ChatGPT Plus subscription to UK ministers
Labour set to freeze income tax thresholds in long-term 'stealth' tax raid
Coca‑Cola explores sale of Costa coffee chain
Trial hears dog walker was chased and fatally stabbed by trio
Restaurateur resigns from government hospitality council over tax criticism
Spanish City funfair shut after serious ride injury
Suspected arson at Ilford restaurant leaves three in critical condition
Tottenham beat Manchester City to go top of Premier League
Bank holiday heatwave to hit 30°C before remnants of Hurricane Erin arrive
UK to deploy immigration advisers to West Africa to block fake visas
Nurse who raped woman continued working for a year despite police alert
Drought forces closures of England’s canal routes, canceling boat holidays
Sweet tooth scents: food-inspired perfumes surge as weight-loss drugs suppress appetites
Experts warn Britain dangerously reliant on imported food
Family of Notting Hill Carnival murder victim call event unmanageable
Bunkers, Billions and Apocalypse: The Secret Compounds of Zuckerberg and the Tech Giants
Ukraine Declares De Facto War on Hungary and Slovakia with Terror Drone Strikes on Their Gas Lifeline
Animated K-pop Musical ‘KPop Demon Hunters’ Becomes Netflix’s Most-Watched Original Animated Film
New York Appeals Court Voids Nearly $500 Million Civil Fraud Penalty Against Trump While Upholding Fraud Liability
Elon Musk tweeted, “Europe is dying”
Far-Right Activist Convicted of Incitement Changes Gender and Demands: "Send Me to a Women’s Prison" | The Storm in Germany
Hungary Criticizes Ukraine: "Violating Our Sovereignty"
Will this be the first country to return to negative interest rates?
Child-free hotels spark controversy
North Korea is where this 95-year-old wants to die. South Korea won’t let him go. Is this our ally or a human rights enemy?
Hong Kong Launches Regulatory Regime and Trials for HKD-Backed Stablecoins
China rehearses September 3 Victory Day parade as imagery points to ‘loyal wingman’ FH-97 family presence
Trump Called Viktor Orbán: "Why Are You Using the Veto"
Horror in the Skies: Plane Engine Exploded, Passengers Sent Farewell Messages
MSNBC Rebrands as MS NOW Amid Comcast’s Cable Spin-Off
AI in Policing: Draft One Helps Speed Up Reports but Raises Legal and Ethical Concerns
Shame in Norway: Crown Princess’s Son Accused of Four Rapes
Apple Begins Simultaneous iPhone 17 Production in India and China
A Robot to Give Birth: The Chinese Announcement That Shakes the World
×